Melanoma, version 2.2013: featured updates to the NCCN guidelines.


Journal Article

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma.

Full Text

Duke Authors

Cited Authors

  • Coit, DG; Andtbacka, R; Anker, CJ; Bichakjian, CK; Carson, WE; Daud, A; Dimaio, D; Fleming, MD; Guild, V; Halpern, AC; Hodi, FS; Kelley, MC; Khushalani, NI; Kudchadkar, RR; Lange, JR; Lind, A; Martini, MC; Olszanski, AJ; Pruitt, SK; Ross, MI; Swetter, SM; Tanabe, KK; Thompson, JA; Trisal, V; Urist, MM; McMillian, N; Ho, M; National Comprehensive Cancer Network (NCCN),

Published Date

  • April 1, 2013

Published In

Volume / Issue

  • 11 / 4

Start / End Page

  • 395 - 407

PubMed ID

  • 23584343

Pubmed Central ID

  • 23584343

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2013.0055


  • eng

Conference Location

  • United States